The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies
Obstetrics & Gynecology Science
;
: 478-483, 2014.
Article
in English
| WPRIM
| ID: wpr-17033
ABSTRACT
OBJECTIVE:
To assess the effects of a gonadotropin-releasing hormone agonist (GnRH-a) depot (Leuprolide acetate) in women with gynecologic cancer receiving chemotherapy while taking a continuous add-back on the prevention of premature ovarian failure.METHODS:
Fourteen premenopausal patients with gynecological malignancies who had undergone conservation of ovaries surgery received a GnRH-a depot plus add-back until chemotherapy was completed. Four weeks thereafter, a hormonal profile (follicle stimulating hormone) was measured.RESULTS:
The mean follicle stimulating hormone level was 15.8 IU/L. All patients exhibited a restoration of ovarian failure during follow-up. One patient became pregnant during the follow-up period.CONCLUSION:
In the short term, GnRH-a appears to protect ovarian function and ability to achieve pregnancy following chemotherapy. The result of our study needs further elucidation in a large randomized controlled trial.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Ovarian Neoplasms
/
Ovary
/
Uterine Cervical Neoplasms
/
Follow-Up Studies
/
Gonadotropin-Releasing Hormone
/
Chemotherapy, Adjuvant
/
Primary Ovarian Insufficiency
/
Drug Therapy
/
Fertility Preservation
/
Follicle Stimulating Hormone
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Female
/
Humans
/
Pregnancy
Language:
English
Journal:
Obstetrics & Gynecology Science
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS